| Expression pattern: |
UP |
| Associated gene: |
WTAP, IGF2BP2, CANT1, CANT1 mRNA |
| Associated microRNA: |
- |
| Biological function: |
Promotes LUAD cell angiogenesis, stemness, proliferation, migration, invasion, tumor growth and tumorigenesis; inhibits apoptosis. |
| Molecular mechanism: |
WTAP induces m6A modification of circEEF2; circEEF2 interacts with IGF2BP2 and stabilizes CANT1 expression in an IGF2BP2-dependent manner. |
| Biological pathway or process: |
angiogenesis (promotes); stemness (promotes); proliferation (promotes); migration (promotes); invasion (promotes); apoptosis (inhibits); m6A modification (other); mRNA stability (promotes); metastasis (promotes) |
| Detected method: |
Q
M
|
| Validation methods: |
RT-qPCR; Microarray; RNase R Treatment; Clinical Sample Validation; Nuclear-Cytoplasmic Fractionation; IF (Immunofluorescence); Transfection; Tube Formation Assay; EdU Staining; Annexin V/PI Flow Cytometry; Transwell Assay; MeRIP / MeRIP-seq; RIP (RNA Immunoprecipitation); Actinomycin D / DRB Stability Assay; Western Blot; In Vivo Animal Model; IHC (Immunohistochemistry); Survival Analysis; Bioinformatics Analysis |
| Clinical significance: |
High circEEF2 expression was associated with shorter survival times in LUAD patients. |
| Description: |
circEEF2 is up-regulated in LUAD tissues and cell lines, and high expression is associated with shorter patient survival. Functionally, circEEF2 promotes angiogenesis, stemness, proliferation, migration, invasion and tumor growth while suppressing apoptosis. Mechanistically, WTAP induces m6A modification of circEEF2, and circEEF2 stabilizes CANT1 through interaction with the m6A reader/RBP IGF2BP2. |
| Confidence score: |
0.8658 |